Literature DB >> 21444705

Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).

Cyril Clavel1, Gilles Peytavin, Roland Tubiana, Cathia Soulié, Catherine Crenn-Hebert, Isabelle Heard, François Bissuel, Houria Ichou, Claudia Ferreira, Christine Katlama, Anne-Geneviève Marcelin, Laurent Mandelbrot.   

Abstract

We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infected women receiving a raltegravir-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median raltegravir concentrations were 235 ng/ml in BP and 93 ng/ml in CVF, with a CVF/BP ratio of approximately 2.3. This good penetration of raltegravir may contribute to the control of viral replication in the female genital tract.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21444705      PMCID： PMC3101453          DOI： 10.1128/AAC.01460-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.

Authors:  S Cu-Uvin; A M Caliendo; S Reinert; A Chang; C Juliano-Remollino; T P Flanigan; K H Mayer; C C Carpenter
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

2.  Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy.

Authors:  Maria Pia De Pasquale; Andrew J Leigh Brown; Susan Cu Uvin; Jessica Allega-Ingersoll; Angela M Caliendo; Lorraine Sutton; Shannon Donahue; Richard T D'Aquila
Journal:  J Acquir Immune Defic Syndr       Date:  2003-09-01       Impact factor: 3.731

3.  Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

Authors:  Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Amanda H Corbett; Angela D M Kashuba
Journal:  Biomed Chromatogr       Date:  2007-10       Impact factor: 1.902

4.  Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Authors:  Julie B Dumond; Rosa F Yeh; Kristine B Patterson; Amanda H Corbett; Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Paul W Stewart; Myron S Cohen; Angela D M Kashuba
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

5.  Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.

Authors:  Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Colin M Kovacs; Roy T Steigbigel; David A Cooper; Ralph Liporace; Robert Schwartz; Robin Isaacs; Lucinda R Gilde; Larissa Wenning; Jing Zhao; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

6.  HIV-1 drug resistance in variants from the female genital tract and plasma.

Authors:  Kimdar Sherefa Kemal; Harold Burger; Douglas Mayers; Kathryn Anastos; Brian Foley; Christina Kitchen; Penelope Huggins; Tamara Schroeder; Gaston Picchio; Sara Back; Wei Gao; William A Meyer; Barbara Weiser
Journal:  J Infect Dis       Date:  2007-01-08       Impact factor: 5.226

7.  Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.

Authors:  Sidonie Lambert-Niclot; Gilles Peytavin; Claudine Duvivier; Catherine Poirot; Michèle Algarte-Genin; Sophie Pakianather; Jean-Luc Meynard; Marc-Antoine Valantin; Jean-Michel Molina; Philippe Flandre; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

8.  Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

Authors:  M Iwamoto; L A Wenning; A S Petry; M Laethem; M De Smet; J T Kost; S A Merschman; K M Strohmaier; S Ramael; K C Lasseter; J A Stone; K M Gottesdiener; J A Wagner
Journal:  Clin Pharmacol Ther       Date:  2007-08-22       Impact factor: 6.875

9.  Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.

Authors:  Awewura Kwara; Allison Delong; Naser Rezk; Joseph Hogan; Heather Burtwell; Stacy Chapman; Carla C Moreira; Jaclyn Kurpewski; Jessica Ingersoll; Angela M Caliendo; Angela Kashuba; Susan Cu-Uvin
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

10.  HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.

Authors:  Maurizio Cianfriglia; Maria Luisa Dupuis; Agnese Molinari; Antonio Verdoliva; Roberta Costi; Clementina Maria Galluzzo; Mauro Andreotti; Andrea Cara; Roberto Di Santo; Lucia Palmisano
Journal:  Retrovirology       Date:  2007-03-07       Impact factor: 4.602
View more
  18 in total

Review 1.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

2.  Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.

Authors:  Caroline Mitchell; Emily Roemer; Evangelyn Nkwopara; Brian Robbins; Theodore Cory; Tessa Rue; Courtney V Fletcher; Lisa Frenkel
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 3.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 4.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

5.  Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.

Authors:  Mackenzie L Cottrell; Kristine B Patterson; Heather M A Prince; Amanda Jones; Nicole White; Ruili Wang; Angela D M Kashuba
Journal:  Antivir Ther       Date:  2015-06-03

6.  Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.

Authors:  Ivana Massud; Amy Martin; Chuong Dinh; James Mitchell; Leecresia Jenkins; Walid Heneine; Chou-Pong Pau; J Gerardo García-Lerma
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

7.  Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.

Authors:  Amie L Meditz; Claire Palmer; Julie Predhomme; Kristina Searls; Becky Kerr; Sharon Seifert; Patricia Caraway; Edward M Gardner; Samantha MaWhinney; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-10       Impact factor: 2.205

8.  Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.

Authors:  Abhijit A Date; Annemarie Shibata; Michael Goede; Bridget Sanford; Krista La Bruzzo; Michel Belshan; Christopher J Destache
Journal:  Antiviral Res       Date:  2012-10-03       Impact factor: 5.970

9.  Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.

Authors:  Milena Veselinovic; Kuo-Hsiung Yang; Craig Sykes; Leila Remling-Mulder; Angela D M Kashuba; Ramesh Akkina
Journal:  Virology       Date:  2016-01-06       Impact factor: 3.616

10.  Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.

Authors:  Jessica L Adams; Kristine B Patterson; Heather M A Prince; Craig Sykes; Benjamin N Greener; Julie B Dumond; Angela D M Kashuba
Journal:  Antivir Ther       Date:  2013-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.